Prostate Cancer UK welcomes ruling on abiraterone in Northern Ireland

  • 01 August 2012

Prostate Cancer UK (formerly The Prostate Cancer Charity) has welcomed news that The Department of Health, Social Services and Public Safety has recommend abiraterone - the breakthrough treatment for men with incurable prostate cancer - for use on the NHS in Northern Ireland.

Prostate Cancer UK (formerly The Prostate Cancer Charity) has welcomed news that The Department of Health, Social Services and Public Safety has recommend abiraterone - the breakthrough treatment for men with incurable prostate cancer - for use on the NHS in Northern Ireland.

Owen Sharp, Chief Executive of Prostate Cancer UK, said: "Prostate Cancer UK has been campaigning to ensure all men who need this groundbreaking drug are able to access it on the NHS regardless of where they live in the UK. We are therefore delighted that abiraterone has been approved for routine use on the NHS in Northern Ireland, following a similar outcome in England & Wales. This is a long overdue piece of good news for all the men with incurable prostate cancer in Northern Ireland.

"Abiraterone can significantly reduce pain and other symptoms as well as extend life by an average of 4 months. We therefore urge local health boards in Northern Ireland to waste no time in putting in place the necessary arrangements to ensure that men who need the drug can access it without delay.

"Delighted though we are with this decision, our campaign will continue until men in Scotland are able to access abiraterone via the NHS too."